BLGO BIOLARGO, INC.
Chemicals & Allied Products · OTC · SEC CIK 880242 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-62.3%
TTM net income YoY-7.8%
TTM EPS YoY—
Revenue 3-yr CAGR-25.8%
Net income 3-yr CAGR—
Margins
Gross margin43.7%
Operating margin-355.4%
Net margin-260.6%
FCF margin—
EBITDA margin-349.9%
Returns
ROE-1,608.5%
ROA-129.8%
ROIC (approx.)—
Asset turnover0.50x
Leverage & solvency
Liabilities / assets165.9%
Debt / equity—
Current ratio0.60x
Interest coverage-14.79x
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.09M | $1.25M | $1.11M | $617,000 | $1.10M | $2.78M | $3.27M | $3.66M |
| Cost of revenue | $574,000 | $573,000 | $657,000 | $489,000 | $731,000 | $1.36M | $1.78M | $1.91M |
| Gross profit | $516,000 | $675,000 | $458,000 | $128,000 | $372,000 | $1.42M | $1.49M | $1.75M |
| R&D expense | $810,000 | $1.09M | $907,000 | $659,000 | $615,000 | $535,000 | $791,000 | $784,000 |
| SG&A expense | $3.23M | $3.31M | $2.75M | $3.43M | $3.09M | $2.69M | $2.52M | $2.58M |
| Operating income | -$3.52M | -$3.73M | -$3.20M | -$4.01M | -$7.18M | -$1.80M | -$1.86M | -$1.62M |
| Interest expense | $317,000 | $285,000 | $188,000 | $188,000 | $144,000 | $115,000 | $93,000 | $32,000 |
| Net income | -$2.60M | -$2.77M | -$2.29M | -$2.95M | -$6.48M | -$1.19M | -$1.16M | -$1.01M |
| EBITDA | -$3.39M | -$3.70M | -$3.17M | -$3.98M | -$7.15M | -$1.77M | -$1.82M | -$1.58M |
| EPS (basic) | -0.01 | -0.01 | -0.01 | — | -0.02 | -0.00 | 0.00 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Banking | ||||||||
| Net interest income | -$302,000 | -$272,000 | -$116,000 | $12,000 | -$64,000 | -$80,000 | -$65,000 | -$21,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $1.53M | $2.19M | $4.12M | $3.88M | $4.55M | $3.47M | $2.56M | $3.55M |
| Receivables | $1.42M | $724,000 | $730,000 | $615,000 | $761,000 | $1.74M | $4.21M | $3.17M |
| Inventory | $322,000 | $303,000 | $292,000 | $310,000 | $409,000 | $444,000 | $369,000 | $330,000 |
| Current assets | $3.54M | $3.50M | $5.45M | $5.11M | $5.78M | $9.19M | $7.22M | $7.14M |
| PP&E, net | $1.68M | $1.77M | $1.64M | $1.64M | $1.66M | $1.66M | $1.70M | $1.74M |
| Total assets | $7.21M | $6.67M | $8.56M | $8.31M | $9.13M | $12.50M | $10.51M | $10.51M |
| Current liabilities | $5.94M | $4.76M | $4.93M | $5.06M | $3.45M | $4.08M | $3.37M | $2.65M |
| Short-term debt | — | — | — | — | $83,000 | $83,000 | — | $66,000 |
| Long-term debt | — | — | — | $2.08M | — | — | — | $1.08M |
| Total debt | — | — | — | $2.08M | — | — | — | $1.15M |
| Total liabilities | $11.96M | $9.40M | $8.75M | $6.79M | $5.92M | $6.44M | $5.42M | $4.46M |
| Shareholders' equity | -$5.26M | -$1.85M | $1.79M | $4.04M | $6.58M | $8.76M | $7.61M | $8.85M |
| Net debt | — | — | — | -$1.80M | — | — | — | -$2.40M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.21M | -$3.06M | -$2.92M | -$1.59M | -$2.76M | -$2.12M | -$1.83M | -$1.92M |
| Investing cash flow | -$43,000 | -$160,000 | -$32,000 | -$13,000 | $256,000 | $192,000 | $0 | -$57,000 |
| Financing cash flow | $1.61M | $1.28M | $3.19M | $952,000 | $3.57M | $2.83M | $866,000 | $1.59M |
| Depreciation & amortization | $128,000 | $31,000 | $34,000 | $33,000 | $34,000 | $36,000 | $42,000 | $40,000 |
| Stock-based compensation | $827,000 | $722,000 | $699,000 | $1.01M | $844,000 | $492,000 | $615,000 | $799,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.